Description
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease.
Catalog No.
DHC12505
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1.8 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P05067
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
LY2062430, CAS: 955085-14-0
Note
For research use only. Not suitable for clinical or therapeutic use.
關鍵字： DHC12505;AICD-57, A4;
武漢佰樂博生物（Biolab Reagents）由五位畢業(yè)于華中科技大學，華中農業(yè)大學，武漢大學等知名高校，且具有二十年工作經驗的生命科學領域頂級研究者創(chuàng)立于2021年，憑借豐富的產品開發(fā)經驗，利用全球領先的技術平臺，引進和整合全球高品質的蛋白、抗體和試劑盒產品。目前，佰樂博生物作為法國AntibodySystem和ProteoGenix在亞洲的獨家總代理，提供近30,000種生命科學試劑，核心產品涵蓋蛋白、抗體和試劑盒，旨在為科研工作者提供專業(yè)、全面、可靠的試劑支持，推動生命科學研究的深入發(fā)展。